Immediate versus delayed surgical intervention for reconstructive therapy of hiv-associated facial lipoatrophy: A randomized open-label study

AIDS Research and Human Retroviruses

Volumn 25, Issue 10, 2009, Pages 979-987

  Narciso, Pasquale ^a   Bucciardini, Raffaella ^b   Tozzi, Valerio ^a   Bellagamba, Rita ^a   Ivanovic, Jelena ^a   Giulianelli, Marinella ^a   Scevola, Sabrina ^a   Palummieri, Antonio ^a   Fragola, Vincenzo ^b   Massella, Maurizio ^b   Fracasso, Luca ^c   De Vita, Roy ^c   Pierro, Paola ^a   Del Maestro, Annamaria ^a   Mirra, Marco ^b   Weimer, Liliana ^b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

POLYACRYLAMIDE GEL; POLYLACTIC ACID;

ADULT; AGED; ANXIETY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ECCHYMOSIS; EDEMA; FACE; FACIAL LIPOATROPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTERMETHOD COMPARISON; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PHYSICIAN; PLASTIC SURGERY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SKIN INJURY; SUBCUTANEOUS NODULE; SURGICAL TECHNIQUE; THERAPY DELAY; THERAPY EFFECT;

ACRYLIC RESINS; ADULT; AGED; DRUG TOXICITY; FEMALE; GELS; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LACTIC ACID; MALE; MIDDLE AGED; POLYMERS; QUALITY OF LIFE; RECONSTRUCTIVE SURGICAL PROCEDURES;

EID: 70449473832     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0029     Document Type: Article

References (41)

1. Palella FJ, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
2. Wu AW and Lamping DL: Assessment of quality of life in HIV disease. AIDS 1994;8:S349359.
3. Department of Health and Human Services (DHHS): Guidelines for the use of antiretroviral agents in HIVinfected adults and adolescents. January 29, 2008. Available at http://www.hivatis.org Accessed: October 14, 2008.
4. Hengel RL, Watts NB, and Lennox JL: Benign symmetric lipomatosis associated with protease inhibitors. Lancet 1997; 350:1596.
5. Roth VR, Angel JB, and Kravcik S: Development of a cervical fat pad following treatment with HIV-1 protease inhibitors. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998 [Abstract 411].
6. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al.: A syndrome of peripheral lipodystrophy, hyperlipidemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F8.
7. Lo JC, Mulligan K, Tai VW, Algren H, and Schambelan M: ''Buffalo hump'' in men with HIV-1 infection. Lancet 1998;351:867-870.
8. Schambelan M, Benson CA, Carr A, et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr 2002;31:257-275.
9. Kotler DP, Rosenbaum K, Wang J, and Pierson RN: Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999;353:2093-2099.
10. Thiebaut R, Daucourt V, Mercie P, et al.: Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 2000;31:1482-1487.
11. Galli M, Polo R, Saint-Marc T, et al.: for the ART-associated Lipodystrophy European Collaborative Study (ALECS group. Guidelines to describe morphologic and metabolic alterations (MMA) under ART: The Marrakech classification. Nutr Metab Disorders HIV Infect 2002;1:25-29.
12. Collins E, Wagner C, and Walmsley S: Psycosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read 2000;10:546-550.
13. Oette M, Juretzko P, Kroidi A, et al.: Lipodistrophy syndrome and self-assessment of well being and physical appearance in HIV-positive patients. AIDS Patient Care STDS 2002;16:413-417.
14. Santos CP, Felipe YX, Braga PE, Ramos D, Lima RO, and Segurado AC: Self-perception of body changes in persons living with HIV/AIDS: Prevalence and associated factors. AIDS 2005;19:S14-S21.
15. Sutinen J: Interventions for managing antiretroviral therapy-associated lipoatrophy. Curr Opin Infect Dis 2005; 18:25-33.
16. Lundgren JD, Battegay M, Behrens G, et al.: European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008;9:72-81.
17. Tai VW, Schambelan M, Algren H, Shayevich C, and Mulligan K: Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting. Clin Infect Dis 2002;35: 1258-1262. (Pubitemid 35305875)
18. Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, Grunfeld C, and Schambelan M: The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2001;86:3480-3487.
19. Ascher B, Coleman S, Alster T, et al.: Full scope of effect of facial lipoatrophy: A framework of disease understanding. Dermatol Surg 2006;32:1058-1069.
20. Von Buelow S and Pallua N: Efficacy and safety of polyacrylamide hydrogel for facial soft-tissue augmentation in a 2-year follow-up: A prospective multicenter study for evaluation of safety and aesthetic results in 101 patients. Plast Reconstr Surg 2006;118:85S-91S.
21. De Santis G, Jacob V, Baccarani A, et al.: Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: A 2-year clinical experience. Plast Reconstr Surg 2008;121:644-653.
22. Moyle GJ, Lysakova L, Brown S, et al.: A randomized openlabel study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004;5:82-87.
23. Cattelan AM, Bauer U, Trevenzoli M, et al.: Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy. Arch Dermatol 2006;142: 362-364.
24. Moyle GJ, Brown S, Lysakova L, and Barton SE: Longterm safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med 2006;7: 181-185.
25. Bechara FG, Gambichler T, Brockmeyer NH, Sand M, Altmeyer P, and Hoffmann K: Hyaluronic acid new formulation: Experience in HIV-associated facial lipoatrophy. Dermatology 2008;217:244-249.
26. Carr A and Law M: An Objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 2003;33:571-576.
27. Brooks R and the EuroQoL Group: EuroQoL: The current state of play. Health Policy 1996;37:53-72.
28. Bucciardini R, Murri R, Guarinieri M, et al.: ISSQoL: A new questionnaire for evaluating the quality of life of people living with HIV in the HAART era. Qual Life Res 2006;15: 377-390.
29. Guaraldi G, Orlando G, Murri R, et al.: Quality of life and body image in the assessment of psychological impact of lipodystrophy: Validation of the Italian version of assessment of body change and distress questionnaire. Qual Life Res 2006;15:173-178.
30. Conti L: Anxiety Status Inventory (ASI) and Self-Rating Anxiety Scale (SAS). In: Repertorio delle scale di valutazione in psichiatria, tomo secondo (Conti L, a cura di). Firenze, S.E.E., 1999, pp. 537-543.
31. Kolb L: Noyes' Modern Clinical Psychiatry, 7th edition, W.B. Saunders, Philadelphia, PA, 1968, pp. 464-466.
32. Lief H: Anxiety reaction. In: Comprehensive Textbook of Psychiatry (Freedman A and Kaplan H, eds.). Williams & Wilkins, Baltimore, MD, 1967, pp. 865-866.
33. Portnoy I: The anxiety states. In: American Handbook of Psychiatry (Arieti S, ed.), Vol.I. Basic Books, New York, 1959, p. 308.
34. Wheeler E, White P, Reed E, and Cohen M: Neurocirculatory asthenia (anxiety neurosis, effort syndrome, neurasthenia). JAMA 1950;142:878-888.
35. Zung WWK: A rating instrument for anxiety disorders. Psychosomatics 1971;12:371-379.
36. Kazis LE, Anderson JJ, and Meenan RF: Effect sizes for interpreting changes in health status. Med Care 1989;27 (3 Suppl.):S178-189.
37. Cohen J: Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Lawrence Erlbaum Associates, Inc. Hillsdale, NJ, 1988.
38. Loutfy MR, Raboud JM, Antoniou T, et al.: Immediate versus delayed polyacrylamide gel injections to correct facial lipoatrophy in HIV-positive patients. AIDS 2007;21:1147-1155.
39. Lafaurie M, Dolivo M, Porcher R, Rudant J, Madelaine I, and Molina JM: Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Acquir Immune Defic Syndr 2005;38:393-398.
40. Orlando G, Guaraldi G, De Fazio, et al.: Long-term psychometric outcomes of facial lipoatrophy therapy: Forty-eightweek observational, nonrandomized study. AIDS Patient Care STDS 2007;21:833-842.
41. Blanch J, Rousaud A, Martinez E, et al.: Factors associated with severe impact of lipodystrophy on quality of life in patients infected with HIV. Clin Infect Dis 2004;38:1464-1470.